Literature DB >> 3197746

Bioavailability and pharmacokinetics of oxazepam.

J Sonne1, S Loft, M Døssing, A Vollmer-Larsen, K L Olesen, M Victor, F Andreasen, P B Andreasen.   

Abstract

Six healthy volunteers received oxazepam 15 mg i.v. and orally at an interval of at least one week. The kinetic variables of i.v. oxazepam were: elimination half-life (t1/2 beta) 6.7 h, total clearance (CL) 1.07 ml.min-1.kg-1, volume of distribution (Vc) 0.27 l.kg-1 (0.21-0.49) and volume of distribution at steady-state (Vss) 0.59 l.kg-1. The intravenous disposition of unbound oxazepam was characterized by a clearance of 22.5 ml.min-1.kg-1 and a distribution volume of 12.3 l.kg-1. After oral oxazepam the peak plasma level was reached in 1.7 to 2.8 h. The plasma t1/2 beta at 5.8 h was not significantly different from the i.v. value. Absorption was almost complete, with a bioavailability of 92.8%. Urinary recovery was 80.0 and 71.4% of the dose after intravenous and oral administration, respectively. Renal clearance (CLR) of the glucuronide metabolite was 1.10 ml.min-1.kg-1 (0.98-1.52). Oxazepam was extensively bound to plasma protein with a free fraction of 4.5%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197746     DOI: 10.1007/bf00561369

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Pharmacokinetics in clinical medicine: oxazepam versus other benzodiazepines.

Authors:  D J Greenblatt; R I Shader; J Koch-Weser
Journal:  Dis Nerv Syst       Date:  1975-05

2.  Disposition of three benzodiazepines after single oral administration in man.

Authors:  M Wretlind; A Pilbrant; A Sundwall; J Vessman
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-01

3.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

4.  ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates.

Authors:  R D Brown; J E Manno
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

Review 5.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

6.  Oxazepam kinetics: effects of age and sex.

Authors:  D J Greenblatt; M Divoll; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1980-10       Impact factor: 4.030

7.  Disposition of oxazepam in relation to age, sex, and cigarette smoking.

Authors:  H R Ochs; D J Greenblatt; H Otten
Journal:  Klin Wochenschr       Date:  1981-08-17

8.  Propylene glycol as a cause of lactic acidosis.

Authors:  M J Kelner; D N Bailey
Journal:  J Anal Toxicol       Date:  1985 Jan-Feb       Impact factor: 3.367

9.  Renal disease, age, and oxazepam kinetics.

Authors:  T G Murray; S T Chiang; H H Koepke; B R Walker
Journal:  Clin Pharmacol Ther       Date:  1981-12       Impact factor: 6.875

10.  Cimetidine spares the glucuronidation of lorazepam and oxazepam.

Authors:  R V Patwardhan; G W Yarborough; P V Desmond; R F Johnson; S Schenker; K V Speeg
Journal:  Gastroenterology       Date:  1980-11       Impact factor: 22.682

View more
  14 in total

1.  Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Authors:  Christian Maass; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

2.  The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam.

Authors:  Beitske E Smink; Berendina J A Hofman; Albert Dijkhuizen; Klaas J Lusthof; Johan J de Gier; Antoine C G Egberts; Donald R A Uges
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

3.  Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects.

Authors:  J Sonne; S Loft; M Døssing; S Boesgaard; F Andreasen
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

4.  The effect of dietary energy and protein deficiency on drug metabolism.

Authors:  O Hamberg; L Ovesen; A Dorfeldt; S Loft; J Sonne
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Single dose pharmacokinetics and pharmacodynamics of oral oxazepam during concomitant administration of propranolol and labetalol.

Authors:  J Sonne; M Døssing; S Loft; K L Olesen; A Vollmer-Larsen; M A Victor; O Hamberg; H Thyssen
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

6.  Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man.

Authors:  J Sonne; J Dragsted; S Loft; M Døssing; F Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans.

Authors:  T Lavé; S Dupin; C Schmitt; B Valles; G Ubeaud; R C Chou; D Jaeck; P Coassolo
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

8.  Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism.

Authors:  J Sonne; S Boesgaard; H E Poulsen; S Loft; J M Hansen; M Døssing; F Andreasen
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

9.  Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.

Authors:  S Toon; B L Holt; S J Langley; F G Mullins; M Rowland; M S Halliday; C Salvadori; B Delalleau
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

10.  Lack of pharmacokinetic interaction between vinpocetine and oxazepam.

Authors:  G Storm; B Oosterhuis; F A Sollie; H W Visscher; W Sommer; H Beitinger; J H Jonkman
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.